Lonza Group AG

Lonza Group AG is a Swiss healthcare company that provides contract development and manufacturing services (CDMO) to pharmaceutical and biotechnology companies. Its shares trade on the Swiss stock exchange SIX under the ticker LONN.

Lonza does not sell its own drug brands; it takes drug candidates developed by its customers from the laboratory stage through clinical trials to commercial-scale manufacturing. The areas it serves include biologic drugs such as monoclonal antibodies, small molecules made by chemical synthesis, cell and gene therapies, antibody-drug conjugates and bringing drugs into their final dosage form. Its customer base ranges from small biotech startups to large drug companies, and the company operates production facilities in Europe, the US and Asia. Long-term manufacturing contracts make up a significant part of its income.

In the CDMO sector, those following Lonza track cyclicality in biotech funding, the timetable for large capacity investments to come online, utilization rates at new facilities, manufacturing demand for high-volume products such as incretin-based (GLP class) drugs, and US regulation targeting foreign biotech suppliers. The Lonza page on Lzzo.com shows the US dollar price; the Turkish lira, euro or pound sterling equivalent can also be selected. A historical chart, technical indicators, the data source and the time of the last update are also provided.